New weight loss drugs coming to Ireland — 7 critical facts.

New weight loss drugs coming to Ireland is a question with a surprisingly long answer, since Mounjaro and Wegovy are far from the end of the story. A genuinely crowded pipeline of oral pills and next-generation injectables is working its way through clinical trials and regulatory review right now.

This guide covers exactly what’s coming next, realistic timelines for each compound, and how they compare to what’s already available. This is educational, research-focused content — none of the compounds discussed here are approved in Ireland or the EU, and nothing here constitutes medical advice. Regulatory status for any medicine can be verified through the Health Products Regulatory Authority (HPRA).

New weight loss drugs coming to Ireland — fact 1: two competing oral pills

The most immediately relevant development is the arrival of oral GLP-1 medication, removing the need for weekly injections entirely. Oral semaglutide for weight management received a positive recommendation from the European Medicines Agency’s expert committee (CHMP) in May 2026 — the first oral GLP-1 medicine recommended for weight loss anywhere in the EU.

Novo Nordisk has indicated a phased launch across selected markets during the second half of 2026, though Ireland’s specific position in that rollout sequence has not been confirmed. Separately, Eli Lilly’s own oral compound, orforglipron, is expected to reach the EU market in 2026 or 2027, meaning Ireland could realistically see two competing oral options within a similar window.

The practical appeal of an oral option is significant for anyone who has hesitated to start GLP-1 treatment specifically due to needle aversion, or who finds weekly self-injection logistically difficult. Early data on oral semaglutide suggests efficacy broadly comparable to the injectable form, though direct head-to-head comparisons across all doses remain limited at this stage of the compound’s development history.

New weight loss drugs coming to Ireland — how to read pipeline news critically

With so many compounds generating headlines simultaneously, it’s worth developing a healthy filter for pipeline news specifically. Early trial results, particularly from Phase 1 or Phase 2 studies, often look remarkably impressive precisely because they’re conducted in small, carefully selected participant groups under closely controlled conditions.

Larger Phase 3 trials, involving thousands of participants across more diverse real-world populations, frequently show more moderate results than the early headline figures suggested — not because the compound failed, but because broader trials capture a wider range of individual responses. This is a normal, expected part of drug development, not a sign of a problem.

• Check which trial phase a result comes from — Phase 3 data carries substantially more weight than early Phase 1 or 2 findings.
• Note the participant numbers — results from a few dozen participants are far less reliable than results from several thousand.
• Distinguish “approved somewhere” from “approved here” — a compound’s regulatory status in the US, UK, or China does not indicate its status in Ireland.
• Treat company press releases with appropriate caution — peer-reviewed publication and regulatory submission carry more weight than a corporate announcement alone.

Oral pill	Developer	EU status
Oral semaglutide	Novo Nordisk	CHMP positive recommendation, May 2026
Orforglipron	Eli Lilly	Expected 2026–2027

New weight loss drugs coming to Ireland — fact 2: CagriSema’s results

CagriSema, Novo Nordisk’s combination of cagrilintide and semaglutide, is among the compounds showing the highest weight loss results reported in current clinical development — figures that have positioned it as a genuine rival to the triple-agonist compounds also in the pipeline.

Combining two different mechanisms — an amylin analogue alongside a GLP-1 agonist — represents a different strategic approach than the multi-receptor agonists like retatrutide, offering an alternative route toward similarly strong results. No regulatory application specific to Ireland has been confirmed at this stage.

New weight loss drugs coming to Ireland — fact 3: retatrutide’s position

Retatrutide, Eli Lilly’s triple GIP/GLP-1/glucagon agonist, remains one of the standout compounds in the entire pipeline, with trial results showing weight loss in the region of 28 to 30% at higher doses — among the strongest figures reported for any compound in development.

As covered in more detail in our dedicated guide on retatrutide’s regulatory status, realistic availability in Ireland remains several years away, with industry estimates suggesting 2028 at the earliest following the completion of Phase 3 trials and full EMA review.

New weight loss drugs coming to Ireland — fact 4: survodutide’s dual mechanism

Survodutide, developed jointly by Boehringer Ingelheim and Zealand Pharma, combines appetite suppression with an energy-burning mechanism — a dual approach distinct from most other compounds currently in the pipeline, which primarily focus on appetite and gastric emptying effects alone.

This energy expenditure angle is a genuinely different mechanistic strategy worth watching, since a medication that increases energy burning alongside reducing appetite could, in principle, produce results through two separate pathways working together rather than relying on appetite suppression alone.

New weight loss drugs coming to Ireland — fact 5: pemvidutide’s dosing promise

Altimmune’s pemvidutide is positioned around a genuinely practical advantage: the potential for monthly, rather than weekly, injection while still delivering strong weight-loss and metabolic benefits. It is currently expected around 2027.

For anyone who finds even weekly injections a barrier, a genuinely effective monthly option would represent a meaningful quality-of-life improvement over every currently approved GLP-1 medication, all of which require weekly dosing at minimum.

New weight loss drugs coming to Ireland — fact 6: mazdutide, approved elsewhere

Mazdutide, also developed by Eli Lilly, holds a genuinely notable distinction: it is the world’s first approved obesity drug to target both GLP-1 and glucagon receptors together. It is licensed to Innovent Biologics and already approved for sale in China under the brand name Xinermai.

This is a useful reminder that “approved somewhere” and “approved in Ireland” are very different things — mazdutide has genuinely cleared a full regulatory approval process, just not the EMA’s, meaning it remains unavailable in Ireland despite already being a commercially available medicine elsewhere in the world.

New weight loss drugs coming to Ireland — fact 7: why the race is so intense

Industry analysts estimate the global market for weight-loss medications could reach approximately €130 billion by 2035 — a scale of commercial opportunity that explains why so many pharmaceutical companies are simultaneously racing to develop competing compounds, each hoping to capture a share of what has become one of the fastest-growing categories in modern medicine.

For patients and prospective patients in Ireland, this intense competition carries a genuine silver lining: more competitors generally means faster innovation, a wider range of mechanisms and dosing options to eventually choose from, and — over time — competitive pressure that could help moderate pricing, even if that effect takes years to materialise fully.

For more on what’s already available, read our guide on Mounjaro cost Ireland or the latest on HSE reimbursement status. Explore our Mounjaro product page, or read patient reviews.

We’ll continue tracking this fast-moving pipeline and update our guides as individual compounds progress through trials and toward regulatory submission — bookmark this page if you want to follow how the picture develops over the coming months.